Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 December 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 193 pages)

 

Export 2384 results:
Author Title [ Type(Desc)] Year
Journal Article
N. S. Nagra, Robinson, D. E., Douglas, I., Delmestri, A., Dakin, S. G., Snelling, S. J. B., Carr, A. J., and Prieto-Alhambra, D., “Antibiotic treatment and flares of rheumatoid arthritis: a self-controlled case series study analysis using CPRD GOLD”, Sci Rep, vol. 9, p. 8941, 2019.
C. J. Currie, Berni, E., Jenkins-Jones, S., Poole, C. D., Ouwens, M., Driessen, S., de Voogd, H., Butler, C. C., and Morgan, C. L., “Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis”, Bmj, vol. 349, p. g5493, 2014.
D. J. Margolis, Bowe, W. P., Hoffstad, O., and Berlin, J. A., “Antibiotic treatment of acne may be associated with upper respiratory tract infections”, Arch Dermatol, vol. 141, pp. 1132-6, 2005.
C. Hopkins, Williamson, E., Morris, S., Clarke, C. S., Thomas, M., Evans, H., Little, P., Lund, V. J., Blackshaw, H., Schilder, A., Philpott, C., Carpenter, J., and Denaxas, S., “Antibiotic usage in chronic rhinosinusitis: analysis of national primary care electronic health records”, Rhinology, 2019.
A. Alonso, Jick, S. S., Jick, H., and Hernan, M. A., “Antibiotic use and risk of multiple sclerosis”, Am J Epidemiol, vol. 163, pp. 997-1002, 2006.
T. Card, Logan, R. F., Rodrigues, L. C., and Wheeler, J. G., “Antibiotic use and the development of Crohn's disease”, Gut, vol. 53, pp. 246-50, 2004.
F. N. Aberra, Brensinger, C. M., Bilker, W. B., Lichtenstein, G. R., and Lewis, J. D., “Antibiotic use and the risk of flare of inflammatory bowel disease”, Clin Gastroenterol Hepatol, vol. 3, pp. 459-65, 2005.
A. A. Sultan, Mallen, C., Muller, S., Hider, S., Scott, I., Helliwell, T., and Hall, L. J., “Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study”, BMC Med, vol. 17, p. 154, 2019.
F. S. Troelsen and Jick, S., “Antibiotic Use in Childhood and Adolescence and Risk of Inflammatory Bowel Disease: A Case-Control Study in the UK Clinical Practice Research Datalink”, Inflamm Bowel Dis, 2019.
C. R. Meier, Derby, L. E., Jick, S. S., Vasilakis, C., and Jick, H., “Antibiotics and risk of subsequent first-time acute myocardial infarction”, Jama, vol. 281, pp. 427-31, 1999.
J. A. Kaye and Jick, H., “Antibiotics and the risk of breast cancer”, Epidemiology, vol. 16, pp. 688-90, 2005.
C. R. Meier, “Antibiotics in the prevention and treatment of coronary heart disease”, J Infect Dis, vol. 181 Suppl 3, pp. S558-62, 2000.
K. Richardson, Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., Myint, P. K., Grossi, C. M., Mattishent, K., Bennett, K., Campbell, N. L., Boustani, M., Robinson, L., Brayne, C., Matthews, F. E., and Savva, G. M., “Anticholinergic drugs and risk of dementia: case-control study”, Bmj, vol. 361, p. k1315, 2018.
S. S. Jick and Terris, B. Z., “Anticonvulsants and congenital malformations”, Pharmacotherapy, vol. 17, pp. 561-4, 1997.
S. S. Jick and Li, L., “Antidepressant drug use and risk of venous thromboembolism”, Pharmacotherapy, vol. 28, pp. 144-50, 2008.
L. E. Derby, Jick, H., and Dean, A. D., “Antidepressant drugs and suicide”, J Clin Psychopharmacol, vol. 12, pp. 235-40, 1992.
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., “Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications”, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
D. Saragoussi, Chollet, J., Bineau, S., Chalem, Y., and Milea, D., “Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) Study”, Int J Clin Pract, vol. 66, pp. 1079-87, 2012.
C. Martinez, Rietbrock, S., Wise, L., Ashby, D., Chick, J., Moseley, J., Evans, S., and Gunnell, D., “Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study”, Bmj, vol. 330, p. 389, 2005.
C. Vasilakis-Scaramozza, Aschengrau, A., Cabral, H., and Jick, S. S., “Antidepressant use during early pregnancy and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 693-700, 2013.
R. Gafoor, Booth, H. P., and Gulliford, M. C., “Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study”, Bmj, vol. 361, p. k1951, 2018.
S. S. Jick, Jick, H., Knauss, T. A., and Dean, A. D., “Antidepressants and convulsions”, J Clin Psychopharmacol, vol. 12, pp. 241-5, 1992.
S. S. Jick, Dean, A. D., and Jick, H., “Antidepressants and suicide”, Bmj, vol. 310, pp. 215-8, 1995.
H. Jick, Kaye, J. A., and Jick, S. S., “Antidepressants and the risk of suicidal behaviors”, Jama, vol. 292, pp. 338-43, 2004.
J. H. Flory, Ellenberg, S., Szapary, P. O., Strom, B. L., and Hennessy, S., “Antidiabetic action of bezafibrate in a large observational database”, Diabetes Care, vol. 32, pp. 547-51, 2009.
S. Hamada and Gulliford, M. C., “Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study”, Age Ageing, vol. 44, pp. 566-73, 2015.
S. Maru, Koch, G. G., Stender, M., Clark, D., Gibowski, L., Petri, H., White, A. D., and Simpson, Jr., R. J., “Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting”, Diabetes Care, vol. 28, pp. 20-6, 2005.
K. W. Hagberg, McGlynn, K. A., Sahasrabuddhe, V. V., and Jick, S., “Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes”, Br J Cancer, vol. 111, pp. 1710-7, 2014.
C. E. Koro, Bowlin, S. J., and Weiss, S. R., “Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication”, Pharmacoepidemiol Drug Saf, vol. 14, pp. 697-703, 2005.
R. Charlton, Garne, E., Wang, H., Klungsoyr, K., Jordan, S., Neville, A., Pierini, A., Hansen, A., Engeland, A., Gini, R., Thayer, D., Bos, J., Puccini, A., Andersen, A. M. Nybo, Dolk, H., and L. van den Berg, deJong-, “Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions”, Pharmacoepidemiol Drug Saf, vol. 24, pp. 1144-54, 2015.
C. Renoux, Dell'Aniello, S., Saarela, O., Filion, K. B., and Boivin, J. F., “Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study”, BMJ Open, vol. 5, p. e008365, 2015.
S. D. Shorvon, Tallis, R. C., and Wallace, H. K., “Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice”, J Neurol Neurosurg Psychiatry, vol. 72, pp. 114-5, 2002.
S. C. Blackburn, Oliart, A. D., Rodriguez, L. A. Garcia, and S. Gutthann, P., “Antiepileptics and blood dyscrasias: a cohort study”, Pharmacotherapy, vol. 18, pp. 1277-83, 1998.
A. Maguire, Mitchell, B. D., and Ruzafa, J. C., “Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study”, BMC Endocr Disord, vol. 14, p. 73, 2014.
S. Dial, Nessim, S. J., Kezouh, A., Benisty, J., and Suissa, S., “Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis”, Br J Clin Pharmacol, vol. 78, pp. 1151-8, 2014.
H. Jick, Vasilakis, C., and Derby, L. E., “Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension”, Epidemiology, vol. 8, pp. 446-8, 1997.
C. Vasilakis-Scaramozza, Aschengrau, A., Cabral, H. J., and Jick, S. S., “Antihypertensive drugs and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 476-82, 2013.
M. W. Myers, Vasilakis, C., Kaufman, M. R., and Jick, H., “Antihypertensive drugs and the risk of idiopathic aplastic anaemia”, Br J Clin Pharmacol, vol. 49, pp. 604-8, 2000.
J. Spoendlin, Voegel, J. J., Jick, S. S., and Meier, C. R., “Antihypertensive drugs and the risk of incident rosacea”, Br J Dermatol, vol. 171, pp. 130-6, 2014.
A. M. Toschke, Gulliford, M. C., Wolfe, C. D., Rudd, A. G., and Heuschmann, P. U., “Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database”, J Hypertens, vol. 29, pp. 154-60, 2011.
A. M. Toschke, Wolfe, C. D., Heuschmann, P. U., Rudd, A. G., and Gulliford, M., “Antihypertensive treatment after stroke and all-cause mortality–an analysis of the General Practitioner Research Database (GPRD)”, Cerebrovasc Dis, vol. 28, pp. 105-11, 2009.
W. A. Blumentals, Brown, R. R., and Gomez-Caminero, A., “Antihypertensive treatment and erectile dysfunction in a cohort of type II diabetes patients”, Int J Impot Res, vol. 15, pp. 314-7, 2003.
S. R. Heckbert, Wiggins, K. L., Glazer, N. L., Dublin, S., Psaty, B. M., Smith, N. L., Longstreth, Jr., W. T., and Lumley, T., “Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population”, Am J Hypertens, vol. 22, pp. 538-44, 2009.
C. Schneider, Adamcova, M., Jick, S. S., Schlagenhauf, P., Miller, M. K., Rhein, H. G., and Meier, C. R., “Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders”, Travel Med Infect Dis, vol. 11, pp. 71-80, 2013.
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., “Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010”, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
S. Hawley, Leal, J., Delmestri, A., Prieto-Alhambra, D., Arden, N. K., Cooper, C., Javaid, M. K., and Judge, A., “Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis”, J Bone Miner Res, vol. 31, pp. 2008-2015, 2016.
G. L. Zornberg and Jick, H., “Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study”, Lancet, vol. 356, pp. 1219-23, 2000.
M. Bloechliger, Ruegg, S., Jick, S. S., Meier, C. R., and Bodmer, M., “Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis”, CNS Drugs, vol. 29, pp. 591-603, 2015.
C. Ishiguro, Wang, X., Li, L., and Jick, S., “Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD”, Pharmacoepidemiol Drug Saf, vol. 23, pp. 1168-75, 2014.
R. Brauer, Smeeth, L., Anaya-Izquierdo, K., Timmis, A., Denaxas, S. C., Farrington, C. P., Whitaker, H., Hemingway, H., and Douglas, I., “Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study”, Eur Heart J, vol. 36, pp. 984-92, 2015.
[Page last reviewed 6 December 2019]